Pipeline of partnering opportunities
Through agreement with our various research partners, Technology Transfer is leading commercialisation for many of our funded programmes. As a result we are currently managing partnering and commercialisation on a portfolio of over 20 translational programmes.
To view the opportunities currently available for partnering please see partnering opportunities.
Therapeutic development
(August 2009)
| Therapeutic focus | Target |
Research primer |
Hit-finding | Hit-to-lead | Lead optimisation | Pre-clinical | IND |
|---|---|---|---|---|---|---|---|
| Malaria | Alternative Compex 1 | Liverpool Scool of Tropical Medicine |
 |
||||
| Oncology | BRCA2 | University of Cambridge |
|
||||
| Oncology | Lysyloxidase | Institute of Cancer Research |
|
||||
| Sepsis | DDAH1 | UCL |
|
||||
| CNS | Retinoic Acid Receptor | Kings College London |
|
||||
| Respiratory | Der p 1 | St Georges |
|
||||
| Cardiovascular | B1 Adrenoreceptor | University of Nottingham |
|
||||
| Endocrine | Glucocorticoid receptor | University of Manchester |
|
||||
| Oncology | BRaf | Institute of Cancer Research |
|
||||
| Endocrine/CNS | 11-B HSD1 | University of Edinburgh |
|
||||
| Endocrine/CNS | PP (Y4) receptor | Imperial College London |
|
Other technologies
(August 2009)
| Focus | Technology |
Research partner |
Development stage |
|---|---|---|---|
| Minimal Invasive Surgery | "i-Snake" (Imaging-Sensing Navigated And Kinematically Enhanced) surgical robot | Imperial College London | Prototype development |
| High-throughput DNA sequencing | Next generation sequencing Enabling technology | Imperial College London | Prototype development |